Soblidotin

Drug Profile

Soblidotin

Alternative Names: TZT-1027; YHI-501

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASKA Pharmaceutical
  • Developer Yakult Honsha
  • Class Antineoplastics; Auristatins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
  • 22 Mar 2007 Soblidotin licensed to Yakult Honsha worldwide
  • 13 Oct 2005 Grelan Pharmaceutical has merged with Teikoku Hormone to form ASKA Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top